ClinicalTrials.gg
CompletedNCT03625622Updated Nov 19, 2026Results posted

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

A Phase 2 interventional study of AR1001 10mg and Placebo in Mild to Moderate Alzheimer's Disease, sponsored by AriBio Co., Ltd.. Completed at 21 sites in United States. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by AriBio Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Results postedStudy documents posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
406th of 1,610
210 · median 73
Started
2019
with 117 others
Phase 2
360 of 1,941
50 open now
Registered
986th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 406th largest by enrollment of the 1,610 interventional ones that give a count, is one of 118 that started in 2019, is one of 360 in phase 2, and was the 986th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks. An optional 26 week extension phase will be available to participants who successfully complete the original phase of the study.

Read the detailed description

Alzheimer's Disease (AD) is the most prevalent neurodegenerative disorder in The United States affecting approximately 5.4 million Americans. AD is characterized by progressive loss in memory and as well as a decline in the ability to learn that is associated with neuronal death. Well known hallmarks of AD are neuritic plaques and neurofibrillary tangles and extensive inflammation. Currently, no treatment has been developed to fully cure or prevent the progression of dementia that is associated with AD.

AR1001 is a polypharmacological drug candidate being developed as a treatment for AD and shows great potential with favorable attributes for a central nervous system (CNS) drug (i.e., high specificity and potency, as well as good pharmacokinetic, bioavailability, CNS penetration, and ensured safety).

The clinical study of AR1001 aims to evaluate the efficacy and safety of AR1001 as a potential treatment for AD. Based on the preclinical results, AR1001 could be an effective treatment option with a mechanism of action that has not been explored for AD indication.

03

Conditions studied

  • Mild to Moderate Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's disease
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 55-80 years at the time of signing the Form.
  2. Subjects (or subject's legally acceptable representative) and caregiver(s) who can sign an Informed Consent to participate in the study. Same caregiver(s) must assist the subject throughout the entire duration of the study.
  3. Subjects who have a diagnosis of probable Alzheimer's disease according to the NIA-AA (National Institute of Aging and Alzheimer's Associations, 2011) criteria with mild to moderate dementia (stage 4 - 5) at screening.
  4. Subjects who have mild-to-moderate cognitive impairment with Score of 16-26 at screening.
  5. Subjects who have an MRI (either 1.5T or 3T) or CT scan performed after onset of symptoms and prior to randomization with findings consistent with the diagnosis of dementia due to Alzheimer's disease and without any other comorbid pathologies.
  6. Subjects who have one (or more) identified adult study partner(s) who, in the opinion of the investigator, has sufficient contact with and knowledge about the subject as to be able to report knowledgeably about the subject's safety, compliance and adherence, cognition, function, and behavior.

Exclusion criteria

Exclusion Criteria

  1. Subjects who are female who are pregnant, nursing, or of and not practicing effective .
  2. Subjects who have signs of delirium.
  3. Subjects who have had a cortical stroke within the preceding 2 years.
  4. Subjects who have any diagnosis of dementia other than that related to Alzheimer's Disease, including concomitant vascular dementia.
  5. Subjects who have a PET scan performed after onset of symptoms with negative amyloid results.
  6. Subjects with a history of myocardial infarction, unstable angina, (NYHA) class III or IV heart failure or stroke within the last 12 months.
  7. Subjects with uncontrolled hypertension (systolic blood pressure >160mm Hg or diastolic blood pressure > 95mm Hg) or hypotension (systolic blood pressure \<90mm Hg or diastolic blood pressure \<50mm Hg).
  8. Subjects who have renal impairment (creatinine > 1.5x ) or hepatic impairment ( or ALT > 2.5x ULN or total > 1.5x ULN).
  9. Subjects who have history of cancer or malignant tumor within 5 years prior to screening with the exception of:

    1. Basal or squamous cell carcinoma of the skin or cervical dysplasia which has been adequately treated.
    2. In situ Grade 1 cervical cancer, fully treated at least 2 years prior to screening and without recurrence.
    3. Prostate cancer, confined to the prostate gland, which has been adequately treated (surgery and/or radiation) with normal or low and stable PSA levels for 2 years prior to screening.
  10. Subjects who have history of untreated thyroid disorder or a seizure disorder.
  11. Subjects who are being treated, or likely to require treatment during the study, with any medications prohibited by the study protocol.
  12. Subjects who have participated in any drug or device trial within the previous 30 days or five half-lives of the investigational drug at screening, whichever one is longer.
  13. Subjects who have any other clinically significant abnormal result in laboratory tests such as abnormally low B12 or high TSH levels, as determined by the Investigator.
  14. Subjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subject's ability to complete the study.
  15. Subjects whose treatment with FDA-approved AD medication (donepezil, galantamine, memantine, rivastigmine or their combinations) has not been stable for at least 3 months prior to screening. Treatment and dosing should remain stable, with no changes throughout the trial.
  16. Subjects who currently take an alpha-1 blocker (Appendix 2).
  17. Subjects who currently take any other phosphodiesterase type 5 (PDE-5) inhibitors (Appendix 2).
  18. Subjects with current use of nitrate agents (Appendix 2).
  19. Subjects who are currently receiving (or unable to stop use for at least 21 days [3 weeks] prior to receiving the first dose of the AR1001 and throughout the study) prescription or non-prescription medications or other products known to be moderate or potent inhibitors/inducers of .
  20. Subjects who have had any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the AR1001 and throughout the study.
  21. Subjects, in the opinion of the Investigator, who are unsuitable to participate in the study.

Extension Phase Continuation Criterion

1. Subjects enrolled in AR1001-ADP2-US01 and completed 26 weeks of assigned dosing.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, orally administered once daily for 26 weeks.

    Drug: Placebo

  • Active comparator
    AR1001 - 10 mg

    Active, AR1001 - 10 mg, orally administered once daily for 26 weeks plus a 26 week extension phase.

    Drug: AR1001 10mg

  • Active comparator
    AR1001 - 30 mg

    Active, AR1001 - 30 mg, orally administered once daily for 26 weeks plus a 26 week extension phase.

    Drug: AR1001 30mg

Interventions

  • DrugAR1001 10mg

    AR1001 Active Oral Tablet 10mg

    Also known as: mirodenafil 10mg

  • DrugPlacebo

    Placebo Oral Tablet

  • DrugAR1001 30mg

    AR1001 Active Oral Tablet 30mg

    Also known as: Mirodenafil 30mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)

    The Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13) is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.

    Time frame: Baseline to Week 26

  2. Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

    The ADSC-CGIC measures change in the areas of mental/cognitive state, behavior, and functioning. ADSC-CGIC is rated on a 7-point Likert-type scale with the following scores: 1 - marked improvement, 2 - moderate improvement, 3 - minimal improvement, 4 - no change, 5 - minimal worsening, 6 - moderate worsening, and 7 - marked worsening.

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Change From Baseline in Mini-mental Status Examination 2 (MMSE-2)

    The Mini-mental Status Examination, 2nd edition (MMSE-2) measures cognitive impairment. Two versions of the instrument were collected: MMSE-2: BV and MMSE-2: SV. The total possible score of the MMSE-2 BV was 16 points; the total possible score of the MMSE-2: SV was 30 points. Higher scores indicate better cognitive function.

    Time frame: Baseline to Week 26

  2. Change From Baseline in Neuropsychiatric Index (NPI)

    The NPI measures 10 dementia-related behavioral symptoms and 2 neurovegetative areas of sleep, appetite and eating disorders. The total score are the sum of the products of frequency and severity for each behavioral symptom. Scale ranges from 0-144 with higher scores indicating greater neuropsychiatric severity.

    Time frame: Baseline to Week 26

  3. Change From Baseline in Global Depression Scale (GDS)

    The GDS measures depression in geriatric subjects with 15 yes/no questions. Each response that indicates despressive symptoms receives a score of 1. Total scores range from 0 (no depression) to 15 (severe depression), with higher scores indicating more depressive symptoms.

    Time frame: Baseline to Week 26

  4. Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version

    The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Family Version is completed by the participant's caregiver and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.

    Time frame: Baseline to Week 26

  5. Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version

    The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Participant Version is completed by the participant and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.

    Time frame: Baseline to Week 26

  6. Treatment Related Adverse Events

    Number of subjects with treatment related adverse events during the 26-week treatment phase as assessed by analysis of adverse events including symptoms and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results

    Time frame: 26 Weeks

Other outcomes

  1. Change From Baseline in ADAS-Cog 13: Monotherapy Subpopulation

    ADAS-Cog 13 is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.

    Time frame: Baseline to Week 26

07

Results

Posted Nov 19, 2026

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestonePlaceboAR1001 - 10 mgAR1001 - 30 mg
Started707070
Completed556157
Not completed15913
Extension Phase
Participant flow — Extension Phase
MilestonePlaceboAR1001 - 10 mgAR1001 - 30 mg
Started07368
Completed06154
Not completed01214

Outcome measures

PrimaryChange From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)

The Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13) is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)-1.327 ± 6.799-1.667 ± 7.226-0.228 ± 7.938
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = .8074
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .4471
PrimaryChange From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

The ADSC-CGIC measures change in the areas of mental/cognitive state, behavior, and functioning. ADSC-CGIC is rated on a 7-point Likert-type scale with the following scores: 1 - marked improvement, 2 - moderate improvement, 3 - minimal improvement, 4 - no change, 5 - minimal worsening, 6 - moderate worsening, and 7 - marked worsening.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)4.29 ± .1264.19 ± .124.32 ± .121
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = .5706
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .8758
SecondaryChange From Baseline in Mini-mental Status Examination 2 (MMSE-2)

The Mini-mental Status Examination, 2nd edition (MMSE-2) measures cognitive impairment. Two versions of the instrument were collected: MMSE-2: BV and MMSE-2: SV. The total possible score of the MMSE-2 BV was 16 points; the total possible score of the MMSE-2: SV was 30 points. Higher scores indicate better cognitive function.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Mini-mental Status Examination 2 (MMSE-2)
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Mini-mental Status Examination 2 (MMSE-2)-0.41 ± 0.305-0.03 ± 0.2830.07 ± 0.295
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = .3566
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .2673
SecondaryChange From Baseline in Neuropsychiatric Index (NPI)

The NPI measures 10 dementia-related behavioral symptoms and 2 neurovegetative areas of sleep, appetite and eating disorders. The total score are the sum of the products of frequency and severity for each behavioral symptom. Scale ranges from 0-144 with higher scores indicating greater neuropsychiatric severity.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Neuropsychiatric Index (NPI)
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Neuropsychiatric Index (NPI)-2.49 ± 1.073-1.67 ± 0.990-0.62 ± 1.024
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = .5761
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .2092
SecondaryChange From Baseline in Global Depression Scale (GDS)

The GDS measures depression in geriatric subjects with 15 yes/no questions. Each response that indicates despressive symptoms receives a score of 1. Total scores range from 0 (no depression) to 15 (severe depression), with higher scores indicating more depressive symptoms.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Global Depression Scale (GDS)
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Global Depression Scale (GDS)-0.58 ± 0.281-0.03 ± 0.260-0.36 ± 0.266
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = .1559
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .5570
SecondaryChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version

The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Family Version is completed by the participant's caregiver and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version1.07 ± 0.6560.93 ± 0.6160.52 ± 0.621
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = 0.8809
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = .5449
SecondaryChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version

The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Participant Version is completed by the participant and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version0.17 ± 0.6240.23 ± 0.5740.36 ± 0.583
Statistical analysis
  • Placebo vs AR1001 - 10 mg · ANCOVA · p = 0.9388
  • Placebo vs AR1001 - 30 mg · ANCOVA · p = 0.8244
Post-hocChange From Baseline in Phosphorylated Tau 181 (pTau181)

pTau181 is a biomarker whose levels have been shown to correlate with Alzheimer's disease severity. Levels of pTau181 were determined from plasma samples.

Time frame:
Baseline to Week 26
Reported as:
Mean · pg/mL
Change From Baseline in Phosphorylated Tau 181 (pTau181)
pg/mLPlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Phosphorylated Tau 181 (pTau181)0.306 ± 0.195-0.294 ± 0.275-0.459 ± 0.288
Statistical analysis
  • Placebo vs AR1001 - 10 mg · t-test, 2 sided · p = .093
  • Placebo vs AR1001 - 30 mg · t-test, 2 sided · p = .034
Post-hocChange From Baseline in Amyloid Beta 42/40 (Aβ 42/40) Ratio

Aβ 42/40 ratio is a biomarker that measures the relative levels of two amyloid protein fragments. Higher ratios are better and indicate a lower likelihood of amyloid buildup. Aβ 42/40 was determined from plasma samples.

Time frame:
Baseline to Week 26
Reported as:
Mean · Unitless (Ratio)
Change From Baseline in Amyloid Beta 42/40 (Aβ 42/40) Ratio
Unitless (Ratio)PlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Amyloid Beta 42/40 (Aβ 42/40) Ratio0.001 ± 0.0010 ± 0.0020.001 ± 0.002
Statistical analysis
  • Placebo vs AR1001 - 10 mg · t-test, 2 sided · p = .483
  • Placebo vs AR1001 - 30 mg · t-test, 2 sided · p = .932
Post-hocChange From Baseline in Glial Fibrillary Acidic Protein (GFAP)

Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein primarily found in astrocytes whose levels correlate with severity of Alzheimer's disease. Levels of GFAP were determined from plasma samples.

Time frame:
Baseline to Week 26
Reported as:
Mean · pg/mL
Change From Baseline in Glial Fibrillary Acidic Protein (GFAP)
pg/mLPlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Glial Fibrillary Acidic Protein (GFAP)23.895 ± 13.69811.892 ± 12.873-7.016 ± 9.540
Statistical analysis
  • Placebo vs AR1001 - 10 mg · t-test, 2 sided · p = .393
  • Placebo vs AR1001 - 30 mg · t-test, 2 sided · p = .042
Post-hocChange From Baseline in Neurofilament Light Chain (NfL)

Neurofilament light chain (NfL) is a neuron-specific protein whose levels correlate with severity of Alzheimer's disease. Levels of NfL were determined from plasma samples.

Time frame:
Baseline to Week 26
Reported as:
Mean · pg/mL
Change From Baseline in Neurofilament Light Chain (NfL)
pg/mLPlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Neurofilament Light Chain (NfL)1.063 ± 1.8580.952 ± 1.813-6.646 ± 6.172
Statistical analysis
  • Placebo vs AR1001 - 10 mg · t-test, 2 sided · p = 0.473
  • Placebo vs AR1001 - 30 mg · t-test, 2 sided · p = 0.052
Post-hocChange From Baseline in Phosphorylated Tau 217 (pTau217)

pTau217 is a biomarker whose levels have been shown to correlate with Alzheimer's disease severity. Levels of pTau217 were determined from plasma samples.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · pg/mL
Change From Baseline in Phosphorylated Tau 217 (pTau217)
pg/mLPlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in Phosphorylated Tau 217 (pTau217)0.037 ± 0.0590.020 ± 0.040-0.118 ± 0.101
Statistical analysis
  • Placebo vs AR1001 - 10 mg · Wilcoxon (Mann-Whitney) · p = 0.530
  • Placebo vs AR1001 - 30 mg · Wilcoxon (Mann-Whitney) · p = .009
Other pre-specifiedChange From Baseline in ADAS-Cog 13: Monotherapy Subpopulation

ADAS-Cog 13 is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.

Time frame:
Baseline to Week 26
Reported as:
Mean · Units on a scale
Change From Baseline in ADAS-Cog 13: Monotherapy Subpopulation
Units on a scalePlaceboAR1001 - 10 mgAR1001 - 30 mg
Change From Baseline in ADAS-Cog 13: Monotherapy Subpopulation-1.756 ± 1.347-0.812 ± 1.634-3.54 ± 1.257
Statistical analysis
  • Placebo vs AR1001 - 10 mg · Wilcoxon (Mann-Whitney) · p = .833
  • Placebo vs AR1001 - 30 mg · Wilcoxon (Mann-Whitney) · p = .294
SecondaryTreatment Related Adverse Events

Number of subjects with treatment related adverse events during the 26-week treatment phase as assessed by analysis of adverse events including symptoms and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results

Time frame:
26 Weeks
Reported as:
Count of participants · Participants
Treatment Related Adverse Events
ParticipantsPlaceboAR1001 - 10 mgAR1001 - 30 mg
Treatment Related Adverse Events423947

Adverse events

Collected over Over 52 weeks of treatment (26 week treatment + 26 week extension). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/70 (0%)6/70 (8.6%)14/70 (20%)
AR1001 - 10 mg1/70 (1.4%)6/70 (8.6%)7/70 (10%)
AR1001 - 30 mg0/70 (0%)8/70 (11.4%)24/70 (34.3%)
AR1001 - 10 mg (Extension)0/73 (0%)2/73 (2.7%)10/73 (13.7%)
AR1001 - 30 mg (Extension)0/68 (0%)2/68 (2.9%)10/68 (14.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboAR1001 - 10 mgAR1001 - 30 mgAR1001 - 10 mg (Extension)AR1001 - 30 mg (Extension)
COVID-19 pneumoniaInfections and infestations0/700/701/700/731/68
Non-cardiac chest painGeneral disorders0/700/700/700/731/68
Transient ischaemic attackNervous system disorders0/700/700/700/731/68
SyncopeNervous system disorders1/700/701/700/730/68
AphasiaNervous system disorders1/700/700/700/730/68
SeizureNervous system disorders0/700/701/700/730/68
Subarachnoid hemorrhageNervous system disorders0/701/700/700/730/68
COVID-19Infections and infestations0/701/701/700/730/68
Abdominal sepsisInfections and infestations0/701/700/701/730/68
Escherichia sepsisInfections and infestations0/700/701/700/730/68
Most frequent other events
Most frequent other events
EventPlaceboAR1001 - 10 mgAR1001 - 30 mgAR1001 - 10 mg (Extension)AR1001 - 30 mg (Extension)
Urinary tract infectionInfections and infestations2/702/704/706/733/68
DizzinessNervous system disorders5/700/701/702/733/68
NauseaGastrointestinal disorders2/701/705/700/731/68
ArthralgiaMusculoskeletal and connective tissue disorders0/700/705/701/731/68
FallInjury, poisoning and procedural complications2/702/705/701/731/68
HeadacheNervous system disorders3/702/704/700/731/68

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
Mean70.4 (58 to 80)70.9 (55 to 81)70.4 (55 to 80)70.6 (55 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
Female484347138
Male22272372
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American128828
White586062180
More than one race0101
Unknown or Not Reported0101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
Hispanic or Latino13131642
Not Hispanic or Latino565752165
Unknown or Not Reported1023
Region of Enrollment
Region of Enrollment(Participants)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
United States707070210
Baseline ADAS-Cog13 Score
Baseline ADAS-Cog13 Score(Units on a scale)PlaceboAR1001 - 10 mgAR1001 - 30 mgTotal
Mean24.57 ± 9.9625.23 ± 9.6226.31 ± 11.0325.37 ± 10.19
08

Study locations

21 sites
  • Advanced Clinical Research, Inc.
    Banning, California 92220, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Meridien Research
    Lakeland, Florida 33805, United States
  • Meridien - Maitland
    Maitland, Florida 32751, United States
  • The Neurology Research Group
    Miami, Florida 33176, United States
  • Accelerated Enrollment Solutions (AES)
    Orlando, Florida 32806, United States
  • IMIC, Inc
    Palmetto Bay, Florida 33157, United States
  • Meridien Research - Spring Hill
    Spring Hill, Florida 34609, United States
  • Meridien Research - St Petersburg
    St. Petersburg, Florida 33709, United States
  • Meridien Research - Tampa
    Tampa, Florida 33634, United States
  • NeuroStudies, LLC
    Decatur, Georgia 30033, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Wake Research - CRCNV
    Las Vegas, Nevada 89106, United States
  • Rapid Medical Research
    Beachwood, Ohio 44122, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Advanced Clinical Research - Cedar Park
    Cedar Park, Texas 78613, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • Advanced Clinical Research, Inc.
    West Jordan, Utah 84088, United States
  • Kingfisher Cooperative, LLC
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease. J Prev Alzheimers Dis. 2025 Nov;12(9):100337. doi: 10.1016/j.tjpad.2025.100337. Epub 2025 Sep 5. PubMed 40912996 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2020, 20 months.

Results were first posted in Nov 2026, 5 years 10 months after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 20 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Aug 10, 2018
StartActual
Apr 1, 2019
Primary completionActual
Dec 21, 2020
CompletionActual
Jun 28, 2021
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Meridien Research - St Petersburg · St. Petersburg, United States
Show 1 removed
  • Meridien Research - St Petersburg · Saint Petersburg, United States
Nov 19, 2026
Primary completion
Dec 22, 2020→Dec 21, 2020
Nov 19, 2026
Eligibility
3 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedSubjects who currently take an alpha-1 blocker (Appendix 2).
  • AddedSubjects who currently take any other phosphodiesterase type 5 (PDE-5) inhibitors (Appendix 2).
  • AddedSubjects with current use of nitrate agents (Appendix 2).
Nov 19, 2026
Interventions
Changed AR1001→AR1001 10mg. Added Drug: AR1001 30mg
Nov 19, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedChange From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)Time frame: Baseline to Week 26
  • AddedChange From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)Time frame: Baseline to Week 26
  • RemovedADAS-Cog 13Time frame: 26 weeks
  • RemovedADCS-CGICTime frame: 26 weeks
Nov 19, 2026
Publications
Results publication added: Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on th… PubMed 40912996 ↗
Nov 19, 2026
Secondary outcomes
1 edited, 6 added, 5 removed
What changed in the outcomes
  • EditedTreatment related adverse eventsRelated Adverse EventsTime frame: 26 weeks → 26 Weeks
  • AddedChange From Baseline in Mini-mental Status Examination 2 (MMSE-2)Time frame: Baseline to Week 26
  • AddedChange From Baseline in Neuropsychiatric Index (NPI)Time frame: Baseline to Week 26
  • AddedChange From Baseline in Global Depression Scale (GDS)Time frame: Baseline to Week 26
  • AddedChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family VersionTime frame: Baseline to Week 26
  • AddedChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant VersionTime frame: Baseline to Week 26
  • RemovedMMSE-2Time frame: 26 weeks
  • RemovedNPITime frame: 26 weeks
  • RemovedGDSTime frame: 26 weeks
  • RemovedC-SSRSTime frame: 26 weeks
  • RemovedQOL-ADTime frame: 26 weeks
  • Addedother outcomeChange From Baseline in ADAS-Cog 13: Monotherapy SubpopulationTime frame: Baseline to Week 26
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Publications Results publication added: Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on th… PubMed 40912996 ↗
    1 site added, 1 site removed
    Show site
    • Meridien Research - St Petersburg · St. Petersburg, United States
    Show 1 removed
    • Meridien Research - St Petersburg · Saint Petersburg, United States
    Primary completion Dec 22, 2020→Dec 21, 2020
    Eligibility 3 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedSubjects who currently take an alpha-1 blocker (Appendix 2).
    • AddedSubjects who currently take any other phosphodiesterase type 5 (PDE-5) inhibitors (Appendix 2).
    • AddedSubjects with current use of nitrate agents (Appendix 2).
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedChange From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)Time frame: Baseline to Week 26
    • AddedChange From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)Time frame: Baseline to Week 26
    • RemovedADAS-Cog 13Time frame: 26 weeks
    • RemovedADCS-CGICTime frame: 26 weeks
    Secondary outcomes 1 edited, 6 added, 5 removed
    What changed in the outcomes
    • EditedTreatment related adverse eventsRelated Adverse EventsTime frame: 26 weeks → 26 Weeks
    • AddedChange From Baseline in Mini-mental Status Examination 2 (MMSE-2)Time frame: Baseline to Week 26
    • AddedChange From Baseline in Neuropsychiatric Index (NPI)Time frame: Baseline to Week 26
    • AddedChange From Baseline in Global Depression Scale (GDS)Time frame: Baseline to Week 26
    • AddedChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family VersionTime frame: Baseline to Week 26
    • AddedChange From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant VersionTime frame: Baseline to Week 26
    • RemovedMMSE-2Time frame: 26 weeks
    • RemovedNPITime frame: 26 weeks
    • RemovedGDSTime frame: 26 weeks
    • RemovedC-SSRSTime frame: 26 weeks
    • RemovedQOL-ADTime frame: 26 weeks
    • Addedother outcomeChange From Baseline in ADAS-Cog 13: Monotherapy SubpopulationTime frame: Baseline to Week 26
    Interventions Changed AR1001→AR1001 10mg. Added Drug: AR1001 30mg
    + 4 other changes: verification date, description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03625622
Lead sponsor
AriBio Co., Ltd.
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Apr 1, 2019
Primary completion
Dec 21, 2020
Completion
Jun 28, 2021
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

James Rock
study director · SVP of global development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion